Skip to Main Content

Paper Details

CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine.
Haematologica
2
2023
CCRL2, CD34+, CD34+ cells, DNA methyltransferase, DNMT, MDS, MDS and secondary acute myeloid leukemia (sAML) cells, MDS-L, MDS-L and TF-1 cells, MDS-L xenograft model, MDS/sAML cell lines, MDS/sAML cells, MDS92, PRC2, TF, TF-1, TF-1 cells, acute myeloid leukemia, azacitidine, myelodysplastic syndrome, myeloproliferative neoplasm, patients, sAML, secondary acute myeloid leukemia cells
Author NameAffiliation
Marios ArvanitisJohns Hopkins University School of Medicine
Mark J LevisSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Mark J LevisSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Srinivasan YegnasubramanianSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Richard J JonesSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Richard J JonesSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
  • 1 - 6

Datasets

Release 1.2